Liquidia Corporation (NASDAQ:LQDA – Get Free Report) Director Stephen Bloch sold 100,000 shares of the firm’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $75.74, for a total value of $7,574,000.00. Following the sale, the director directly owned 880,073 shares of the company’s stock, valued at $66,656,729.02. The trade was a 10.20% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Liquidia Trading Up 2.0%
NASDAQ LQDA traded up $1.50 during trading hours on Wednesday, reaching $75.54. The company had a trading volume of 2,085,398 shares, compared to its average volume of 1,848,579. The stock has a 50-day moving average of $54.51 and a 200 day moving average of $42.91. Liquidia Corporation has a 1-year low of $11.85 and a 1-year high of $77.09. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18. The stock has a market capitalization of $6.72 billion, a P/E ratio of 539.61 and a beta of 0.58.
Liquidia (NASDAQ:LQDA – Get Free Report) last announced its earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.11. The company had revenue of $132.87 million during the quarter, compared to analyst estimates of $119.44 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The business’s revenue for the quarter was up 4187.1% on a year-over-year basis. As a group, research analysts anticipate that Liquidia Corporation will post 2.97 earnings per share for the current fiscal year.
Analysts Set New Price Targets
View Our Latest Analysis on Liquidia
Institutional Investors Weigh In On Liquidia
Large investors have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Liquidia by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock valued at $556,000 after acquiring an additional 1,700 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in Liquidia by 10.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock worth $12,703,000 after acquiring an additional 82,955 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Liquidia by 15.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock valued at $1,796,000 after purchasing an additional 16,022 shares during the last quarter. Creative Planning raised its holdings in shares of Liquidia by 40.7% in the 2nd quarter. Creative Planning now owns 26,840 shares of the company’s stock valued at $334,000 after purchasing an additional 7,765 shares in the last quarter. Finally, Legal & General Group Plc raised its holdings in shares of Liquidia by 13.4% in the 2nd quarter. Legal & General Group Plc now owns 94,152 shares of the company’s stock valued at $1,174,000 after purchasing an additional 11,111 shares in the last quarter. 64.54% of the stock is owned by hedge funds and other institutional investors.
Liquidia Company Profile
Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.
The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).
Featured Stories
- Five stocks we like better than Liquidia
- Why KB Home Could Reward Patient Investors Later
- Meta’s Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time
- Tesla’s New NHTSA Probe Lands at the Worst Possible Time
- Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus
Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.
